Drug Trial Radar · NCT03400033
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
Last checked: Nov 19, 2026Latest source record: Jul 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
Sep 5, 2018
Primary completion
Jun 19, 2020
Study completion Jun 19, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care. This study includes a 4 week Screening Period, a 52 week Treatment Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62 weeks. Approximately 402 subjects will be randomized to receive either daprodustat three times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.
Conditions
- Anaemia
Interventions
Daprodustat tabletsDrug
Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Matching placebo tabletsDrug
Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Epoetin alfa vialsDrug
Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
Saline vials or bagsDrug
0.9% sodium chloride saline vials or bags administered by the IV route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Locations
91 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Fresno, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Paramount, California
GSK Investigational Site
Middlebury, Connecticut
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
Pittsfield, Massachusetts
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
College Point, New York
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Lufkin, Texas
GSK Investigational Site
Alexandria, Virginia
GSK Investigational Site
Hampton, Virginia
GSK Investigational Site
Norfolk, Virginia
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
GSK Investigational Site
Pergamino, Buenos Aires, Argentina
GSK Investigational Site
Sarandí, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Parkville, Victoria, Australia
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Curitiba, Paraná, Brazil
GSK Investigational Site
Passo Fundo, Rio Grande do Sul, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Bayonne, France
GSK Investigational Site
Epagny Metz-Tessy, France
GSK Investigational Site
Le Mans, France
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.